BioAmber (NYSE: BIOA) reported Q2 EPS of ($0.20), $0.07 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.43 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.